<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="24962">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01785914</url>
  </required_header>
  <id_info>
    <org_study_id>ALL-TO-2012</org_study_id>
    <nct_id>NCT01785914</nct_id>
  </id_info>
  <brief_title>Retrospective Evaluation of the Clinical Results Obtained in Patients With Acute Lymphoblastic Leukemia Treated at the San Giovanni Battista Hospital.</brief_title>
  <acronym>ALL</acronym>
  <official_title>Retrospective Evaluation of the Clinical Results Obtained in Patients With Acute Lymphoblastic Leukemia Treated at the San Giovanni Battista Hospital.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera San Giovanni Battista</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera San Giovanni Battista</source>
  <oversight_info>
    <authority>Italy: Ministery of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study provides for the collection of a series composed by patients with newly diagnosed
      of acute lymphoblastic leukemia in the period 1999-2011. This collection is carried out with
      retrospective investigation, through the review of paper and electronic records and data
      cards in large part already collected as part of study protocols &quot;GIMEMA&quot; or &quot;BFM&quot; or &quot;NILG&quot;
      approved by the Ethics Committee of Hospital. The purpose of data collection is to check
      with retrospective predictability of classical risk factors in relation to disease response,
      and overall survival of the event-free survival, to estimate the cumulative incidence of
      competitive events such as the emergence of disease, acute and chronic transplant, the
      transplant-related mortality and relapse of disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Disease: Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Acute lymphoblastic leukemia patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patients with newly diagnosed of acute lymphoblastic leukemia enrolled from 1999 to 2011
        at the Division of Hematology, Molinette University Hospital and candidates for
        therapeutic approach with curative intent.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benedetto Bruno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Divisione di Ematologia-Città della Salute e della Scienza di Torino</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benedetto Bruno, MD</last_name>
    <phone>+390116336728</phone>
    <email>benedetto.bruno@unito.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Benedetto Bruno, MD</last_name>
    <phone>+390116336728</phone>
    <email>gismm2001@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benedetto Bruno, MD</last_name>
      <phone>+390116336728</phone>
      <email>benedetto.bruno@unito.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 5, 2013</lastchanged_date>
  <firstreceived_date>February 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera San Giovanni Battista</investigator_affiliation>
    <investigator_full_name>Benedetto Bruno</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
